Claims for Patent: 11,173,209

Summary for Patent: 11,173,209

Title:	Compositions for drug administration
Abstract:	The present invention provides compositions and methods and for increasing the bioavailability of therapeutic agents in a subject. The compositions include at least one alkyl glycoside and at least one therapeutic agent, wherein the alkylglycoside has an alkyl chain length from about 10 to about 16 carbon atoms.
Inventor(s):	Maggio Edward T.
Assignee:	AEGIS THERAPEUTICS, LLC
Application Number:	US16678347
Patent Claims:	1. A method of treating a condition ameliorated by epinephrine in a subject , said method comprising intranasally administering to the subject in need thereof a composition consisting of: a) epinephrine , b) an alkylglycoside , and c) inactive excipients ,wherein the alkylglycoside has an alkyl chain including between 8 to 20 carbons and the alkylglycoside concentration is between about 0.001% and 10.0% (w/v),wherein the composition is an aqueous solution formulated for intranasal delivery to the subject.2. The method of claim 1 , wherein the alkylglycoside is selected from the group consisting of undecyl maltoside claim 1 , dodecyl maltoside claim 1 , tridecyl maltoside claim 1 , tetradecyl maltoside claim 1 , sucrose mono-dodecanoate claim 1 , sucrose mono-tridecanoate claim 1 , and sucrose mono-tetradecanoate.3. The method of claim 2 , wherein the alkylglycoside is dodecyl-beta-D-maltoside.4. The method of claim 1 , wherein the alkylglycoside concentration is between about 0.05% and 0.5% (w/v).5. The method of claim 1 , wherein the composition provides a Cmax for the epinephrine in the subject that is about 2 fold or greater as compared to administration without alkylglycoside.6. The method of claim 1 , wherein the composition provides a Tmax for the epinephrine in the subject that is about 2 fold or less as compared to administration without alkylglycoside.7. The method of claim 1 , wherein the composition provides a Tmax for the epinephrine of about 0.3 hours or less in the subject.8. The method of claim 1 , wherein the composition has a pH of about 2.0 to 5.0.9. The method of claim 1 , wherein the inactive excipients are selected from citric acid claim 1 , sodium citrate claim 1 , propylene glycol claim 1 , glycerin claim 1 , ascorbic acid claim 1 , sodium metabisulfite claim 1 , ethylenediaminetetraacetic acid (EDTA) disodium claim 1 , benzalkonium chloride claim 1 , sodium hydroxide claim 1 , or a combination thereof.10. The method of claim 1 , wherein the inactive excipients are selected from benzalkonium chloride claim 1 , EDTA claim 1 , or a combination thereof.